Changes

<p>Celera's mission is to discover and develop meaningful new therapies that improve human health. We are applying our diverse genomicsengaged in the discovery and development of targeted therapies for cancer, bioinformatics, medicinal chemistry autoimmune and inflammatory diseases (a category that includes diseases such as asthma and biology technology platforms to rheumatoid arthritis). To identify and validate drug targetsand diagnostic marker candidates, and to discover novel therapeutic candidates, awe are leveraging capabilities in proteomics , bioinformatics and genomics . We are also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. </p><p>In the area of cancer, Celera has been identifying cell surface proteins associated with four types of cancer&mdash;lung, colon, pancreatic and breast&mdash;that may represent targets for new drugs or diagnostics. Its discoveries from proteomics have recently led to separate collaborations with Abbott Laboratories and Seattle Genetics supporting the discovery and development of targeted therapies for cancer. <br /p><br p>Celera Genomics has focused its efforts on advancing its small molecule programs, and on the discovery of associations between cell surface proteins and cancer. Our most advanced unpartnered small molecule programs include histone deacetylase (HDAC) inhibitors for cancer and factor VIIa inhibitors as oral and/or parenteral drugs for anticoagulation indications. We have expanded our development organization to support the advancement of internal programs into clinical trials. </p> <h2>Additional Information</h2>